NUCLEOLIN and neoplasm: Treatment of a metastatic RCC patient who failed from treatment with prior TKI with AS1411, a DNA aptamer targeting nucleolin, resulted in an 84% reduction in tumor burden and inhibition of tumor progression for 2 years [39].